Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis
European Journal of Pharmacology · 2025
DOI: 10.1016/j.ejphar.2025.178148 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Huimin Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China; Postg…. Hauptthemen laut MEDLINE: Pancreatitis, Hypertriglyceridemia, Antibodies, Monoclonal, Humanized, PCSK9 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The primary goal of treatment for hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is to rapidly reduce blood triglyceride (TG) level to below 5.65 mmol/L. Evolocumab with a significant lipid-lowering effect, has been widely used for cardiovascular diseases. However, it has been rarely explored in HTG-AP. METHODS: HTG-AP patients, who were admitted between January 2022 and February 2024, were retrospectively reviewed. They were further divided according to the use of evolocumab. Blood TG levels before treatment were compared with those after 1-2 days, 3-4 days, and 5-7 days of treatment. RESULTS: Overall, 62 patients were included, of whom 30 (48.4 %) were in the evolocumab group and 32 (51.6 %) were in the non-evolocumab group. The median pre-treatment TG levels were not significantly different between them (22.17 mmol/L vs 16.94 mmol/L, P = 0.108). Blood TG levels after 1-2 days (P = 0.016) and 5-7 days (P = 0.007) were significantly higher in the evolocumab group than the non-evolocumab group. The proportion of TG < 5.65 mmol/L after 1-2 days (6/24 vs 11/23, P = 0.104) and 3-4 days (10/19 vs 14/20, P = 0.265) was not significantly different between them, but that after 5-7 days (9/15 vs 19/20, P = 0.033) was significantly lower in the evolocumab group than the non-evolocumab group. CONCLUSION: The addition of evolocumab to conventional lipid-lowering therapy did not produce any additional benefit in the reduction of blood TG levels in HTG-AP patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China; Postgraduate College, Dalian Medical University, Dalian, China.
- Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China; Postgraduate College, China Medical University, Shenyang, China.
- Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China.
- Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China; Postgraduate College, Dalian Medical University, Dalian, China; Postgraduat…
Zitieren
APA
Chen, H., Li, X., Chen, J., Zhao, Y., Zhang, W., Li, H., & Qi, X. (2025). Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178148
Vancouver
Chen H, Li X, Chen J, Zhao Y, Zhang W, Li H, et al. Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178148
BibTeX
@article{Chen2025,
author = {Chen, Huimin and Li, Xiaotong and Chen, Jihong and Zhao, Yarui and Zhang, Wenxiu and Li, Hongyu and Qi, Xingshun},
title = {Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis},
journal = {European Journal of Pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.178148}
}
EUVIMED